Emre Atay, Ayhan Vurmaz, Selvihan Beysel, Serkan Gökaslan, Erhan Bozkurt, Ayşe Ertekin

Evaluation of relationship among polycystic ovarysyndrome, atherogenic index of plasma, and highsensitive C reactive protein

Aim: In this study, we aimed to investigate the relationship among cardiovascular risk factors (CRFs), atherogenic index of plasma(AIP) and high-sensitivity C-reactive protein (hs-CRP) levels in polycystic ovary syndrome (PCOS) patients and identify risks earlier.Materials and Methods: 131 patients diagnosed with PCOS according to Rotterdam criteria and 140 healthy controls were includedfrom August 2019 to October 2019. Blood samples were done in the early follicular phase of the patients and were done after 10-12hours of fasting. Results: AIP and hs-CRP levels were higher in PCOS group (p

PDF

___

1. Morgante G, Massaro MG, Di Sabatino A, et al. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecol Endocrinol 2018;34:4-9.
2. Sova H, Unkila-Kallio L, Tiitinen A, et al. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes. Gynecol Endocrinol 2019;35:595-600.
3. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and metaAnalysis. Hum Reprod 2016;31:2841-55.
4. Wild RA. Polycystic ovary syndrome: A risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35-43.
5. Carmina E. Cardiovascular risk and events in polycystic ovary syndrome. Climacteric 2009;12:22-5.
6. Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1357-63.
7. Parinita K. of serum lipid profile in individuals residing in and around Nalgonda. Int J Pharm Bio Sci 2012;2:110-6.
8. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81:18-25.
9. Talbott EO, Zborowski J V., Boudreaux MY, et al. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:6061-6.
10. Orio F, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in young normalweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588-93.
11. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-40.
12. Dobiášová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate inapoblipoprotein-depleted plasma (FERHDL). Clin Biochem 2001;34:583-8.
13. Haverkate F, Thompson SG, Pyke SDM, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
14. Report of a WHO consultation. Obesity: preventing and managing the global epidemic. WHO Library Cataloguing-in-Publication Data, Geneva, 2000.
15. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA 2001;285:2486-97.
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
17. Dobiásová M. AIP-atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek 2006;52:64-71.
18. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
19. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005;90:5711-6.
20. Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012;33:812-41.
21. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
22. Luck J, Nestler SP, Simon MA. The residency review committee for orthopaedic surgery. Establishing the standard for quality education. J Bone Jt Surg - Ser A 2001;83:466-72.
23. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821-6.
24. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;2:110-6.
25. Khazaál MS. Atherogenic Index of Plasma (AIP) As a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (Cholesterol Ratios). J Med 2013;6:1506-13.
26. Naito HK. The Association of serum lipids, lipoproteins, and apolipoproteins with coronary artery disease assessed by coronary arteriography. Ann N Y Acad Sci 1985;454:230-8.
27. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992;85:37-45.
28. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran 2015;29:240.
29. Gaziano JM, Hennekens CH, O’Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997;96:2520-5.
30. Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 2004;50:1184-8.
31. Ridker P, Hennekens C, Buring J, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. Ital Heart J Suppl 2000;342:836-43.
32. Michigan A, Johnson TV, Master VA. Review of the relationship between C-reactive protein and exercise. Mol Diagnosis Ther 2011;15:265-75.
33. Ridker PM, Rifai N, Rose L, et al. Comparison of C-Reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557- 65.
34. Ridker PM, MacFadyen JG, Fonseca FAH, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the use of statins in prevention. Circ Cardiovasc Qual Outcomes 2009;2:616-23.
35. Vodolazkaia A, Bossuyt X, Fassbender A, et al. A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis. Reprod Biol Endocrinol 2011;9:113.
36. Coner A, Aydinalp A, Muderrisoglu H. Evaluation of hsCRP and sLOX-1 levels in moderate-to-high risk acute coronary syndromes. Endocr Metab Immune Disord Drug Targets 2020;20:96-103.
37. Boulman N, Levy Y, Leiba R, et al. Increased C-Reactive Protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular Disease. J Clin Endocrinol Metab 2004;89:2160-5.
38. Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741-60.
39. González F, Rote N, Minium J, et al. Increased activation of nuclear factor κB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1508-12.
40. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003;107:499-511